Dr. Chuang, a a Medical Director in Early Clinical Development in the PD/Movement Disorders Neurodegeneration Unit at Biogen, discussed the SCA3 ASO (anti-sense oligonucleotide) study that is currently recruiting, review important aspects of Biogen’s clinical trial, and discuss how the drug will be studied for Ataxia.
Ещё видео!